Business Description
Acurx Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00510M1045
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.66 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -33.6 | |||||
3-Year EPS without NRI Growth Rate | -33.6 | |||||
3-Year FCF Growth Rate | -30.1 | |||||
3-Year Book Growth Rate | 4.5 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 42.62 | |||||
9-Day RSI | 49.11 | |||||
14-Day RSI | 51.64 | |||||
6-1 Month Momentum % | -44.74 | |||||
12-1 Month Momentum % | -28.66 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.93 | |||||
Quick Ratio | 2.93 | |||||
Cash Ratio | 2.87 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.9 | |||||
Shareholder Yield % | -20.89 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -307.2 | |||||
ROA % | -197.71 | |||||
ROIC % | -8042.59 | |||||
ROCE % | -307.19 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 6.22 | |||||
Price-to-Tangible-Book | 6.41 | |||||
EV-to-EBIT | -1.81 | |||||
EV-to-EBITDA | -1.81 | |||||
EV-to-FCF | -2.62 | |||||
Price-to-Net-Current-Asset-Value | 6.41 | |||||
Price-to-Net-Cash | 6.61 | |||||
Earnings Yield (Greenblatt) % | -55.34 | |||||
FCF Yield % | -28.79 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Acurx Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.089 | ||
Beta | 0 | ||
Volatility % | 297.68 | ||
14-Day RSI | 51.64 | ||
14-Day ATR (€) | 0.081494 | ||
20-Day SMA (€) | 2.19 | ||
12-1 Month Momentum % | -28.66 | ||
52-Week Range (€) | 1.21 - 5.45 | ||
Shares Outstanding (Mil) | 15.84 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Acurx Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Acurx Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Acurx Pharmaceuticals Inc Frequently Asked Questions
What is Acurx Pharmaceuticals Inc(STU:3ZO)'s stock price today?
When is next earnings date of Acurx Pharmaceuticals Inc(STU:3ZO)?
Does Acurx Pharmaceuticals Inc(STU:3ZO) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |